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INTRODUCTION & OBJECTIVES METHODS
Since October 2002 the surveillance of Invasive Meningococcal
Disease (IMD) in Portugal includes a mandatory laboratory
notification in addition to the clinical notification, which had been
mandatory since 1939. The Directorate-General of Health
manages the epidemiological information and interventions.
The National Reference Laboratory (NRL) of Neisseria
meningitidis at the National Institute of Health Dr. Ricardo Jorge,
Lisbon (NIH) conduct a hospital laboratory network implemented
throughout the country in 2002, the VigLab-DM, which supports
the laboratory component of the surveillance. Meningococcal
isolates and negative culture clinical samples are mandatory to
been send do NRL, where lab confirmation and genotyping are
proceed.
Surveillance data is, therefore, the basis for prevention and
control policies. Vaccination against MenC was available since
2002 and, in 2006, the vaccine was introduced in the national
immunization programme, aimed to children under one year of
age. Since 2007 the number of invasive C strains became
residual.
In April 2014, the multi-component vaccine 4CMenB was
introduced in the market.
The aim of this study is to perform a descriptive analysis of
laboratory-based surveillance of IMD from 2016 to 2018.
The case definition of IMD is in accordance with ECDC guidelines.
Suspected cases were confirmed by real time PCR targeting ctrA and
sodC with Taqman probes (1). Groups were identified by PCR (1).
DNA characterization present in clinical samples included porA, FetA
and MLST, was performed through amplicon-based Sanger
sequencing (2,3). Isolates genotyping was done by Whole Genome
Sequencing.
RESULTS
CONCLUSIONS References
 The incidence rate of IMD has been decreasing in Portugal since 2003. In the 3-year period from 2016 to 2018 the incidence rate was low
(0.41-0.59 per 100,000 people) (Fig. 1) and under the average reported in the European countries (0.62-0.63 per 100,000 people);
 The data quality from the lab based surveillance system has been improving. ≥ 90% of cases were laboratory confirmed in the last 5 years (Fig. 2);
 Group B has been the most frequent, mostly belonging to cc41/44 and cc213;
 It has been observed an increasing number of cases due to MenW cc11;
 It is important to continue the IMD surveillance in order to evaluate the prevention and control policies implemented and improve them based on
updated data.
(1) Laboratory methods for the diagnosis of meningitis caused
by Neisseria meningitis, Streptococcus pneumonia and
haemophilus influenza. CDC, WHO Manual, 2 nd Edition,
2011
(2) Paula Molling, et al. 2002.Direct and Rapid Identification
and Genogrouping of Meningococci and porA Amplification
by LightCycler PCR. J. Clin. Microb. 40.12 p 4531-4535.
(3) Maiden MC, et al. 1998. Multilocus sequence typing: a
portable approach to the identification of clones within
populations of pathogenic microorganisms. Proc Natl Acad
Sci U S A 95: 3140–3145.
Figure 2 - Proportion of confirmed and probable/possible
cases of IMD registered in Portugal, 2003-2018.
Figure 1 – Incidence rate/100,000 of IMD in Portugal, 2003-2018:
global incidence, serogroups B, C and other or unknown serogroups.
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The incidence rate of IMD has been decreasing since it has been monitored through the laboratory based
surveillance system. In the 3-year period 2016-2018 the incidence rate ranged from 0.41 to 0.59 /100.000
inhabitants (Fig. 1).The vaccine MenC was introduced in the National Immunization Program in 2006. The
vaccine MenB was introduced in the free market in 2014.
The proportion of lab confirmed cases is annually monitored and is one parameter of the surveillance
evaluation (Fig. 2).
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Figure 4 – Percentage of serogroups per year of onset,
Portugal, 2003-2018.
Year of
onset
Group
B
Group
C
Group
W
Group
Y 
NG
Other
groups
UN Total
2003 70 51 6 0 2 2 15 146
2004 93 15 4 4 0 2 7 125
2005 98 16 2 2 2 0 17 137
2006 77 15 1 5 1 0 4 103
2007 82 4 1 3 1 0 7 98
2008 57 0 0 3 1 1 1 63
2009 58 1 0 2 0 1 5 67
2010 49 6 0 0 3 2 22 82
2011 55 2 0 10 1 0 10 78
2012 45 3 1 4 2 0 14 69
2013 48 2 1 3 0 0 7 61
2014 33 2 0 5 4 0 10 54
2015 48 4 0 7 2 0 5 66
2016 32 0 1 6 0 0 2 41
2017 32 2 2 4 0 1 8 49
2018 41 5 5 6 0 0 2 59
Total
918 
(70.7%)
128 
(9.9%)
24 
(1.8%)
64 
(4.9%)
19 
(1.5%)
9 
(0.7%)
136 
(10.5%)
1298
Cases due to serogroup B have been always the most frequent (70.7% of all confirmed cases). Cases
due to serogroup C dramatically decreased since 2007 and are since there mostly reported in adults
and/or non-residents, with the exception of one case occurred in an unvaccinated baby under one year of
age, in 2014. It was observed an increasing number of cases due to W strains that has been maintained
in 2019 (data not shown) (Table 1, Fig.4).
Table 1 – Number of invasive strains by serogroup and year of onset,
Portugal 2003-2018
NG= Non-groupable
UN= Unknown
Since the annual number of cases is low, in order to get
a more robust data, the incidence rate (IR) by age
group was analyzed considering accumulated data in
three successive 4-year period, starting in 2007.
The IR by age group showed the highest rate in children
under one year of age, decreasing significantly in the
group of 1 to 4 years of age and remaining very low
after 10-14 years of age Although this pattern is the one
observed in 2007-2010, there is a clear IR decreasing in
the ages up to 1-4 years, in the period 2015-2018
(Figure 3).
*average value
Figure 3 – Incidence rate by age group, Portugal 2007-2018
Genotypes – data from a 3-year period 2016-2018
86 group B strains (MenB) (82% of all B stains) were characterized. They assigned to 13
different clonal complexes (cc) and 10.5% of them were unassigned (UA) to cc.
B strains were mostly belonging to cc41/44 (29.1%) followed by cc213 (16.3%) (Fig 5 and 6).
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Figure 5 – Proportion of group B strains assigned to clonal complexes,
2016-2018
Figure 6 – Distribution of group B strains
clonal complexes by year of onset
Group Y strains (MenY) were the second most frequent. The 15 characterized strains (93.8% of
all Y stains) were mostly assigned to cc23. Clonal complex 103 represented 26.7% of the
studied strains (Fig 7). Cases occurred in all age groups (Fig 8).
Seven Group C strains were characterized (85.7% from all MenC strains). All but one were
assigned to cc11. Four strians had the same finetyping antigens P1.5,2:F3-6.
All Group W strains (MenW) were characterized. 6 strains were assigned cc11 (75%), mostly
with finetyping antigens P1.5,2:F1-1, and 2 strains were cc22, both P1.18-1,3:F4-1 (Fig. 9 and
10). According to Antigen Sequence Types (BAST), MenW cc11 were classified into BAST 2, 
excepting one strain in which NadA peptide was absent.  
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Year of onset
Nº of cases 
MenW
Age of
patient
Genotype
2016 1 6 years W:P1.18-1,3:F4-1:St184 cc22
2017 2
88 years W:P1.5,2:F1-1:ST11cc11
62 years W:P1.5,2:F1-1:ST11cc11
2018 4
47 years W:P1.18-1,3:F4-1:St184 cc22
70 years W:P1.5,2:F1-1:ST11cc11
97 years W:P1.5,2:F1-1:ST11cc11
52 years W:P1.5,20:F1-1:ST11cc11
7 months W:P1.5,2:F1-1:ST11cc11
2019             
(May)
5
15 months W:P1.5,2:F1-1:ST11cc11
12 months W:P1.18-1,3:F4-1:ST8044 cc22
53 years W:P1.5,2:F1-1:ST11cc11
7 months W:P1.5,2:F1-1:ST11cc11
5 months W:P1.5,2:F1-1:ST11cc11
83 years WGS ongoing
Table 2– Age distribution of patients with IMD due to MenW,
2016-2019
Figure 9 – Number of MenW strains by clonal
complex.
Figure 7 – Proportion of MenY strains by clonal
complex.
Figure 8 – Incidence rate of IMD due to MenY.
<1 1-4 5-9 10-14 15-19 20-24 25-44 ≥45
2007-2010 * 21,8 7,5 2,4 0,5 0,7 0,2 0,2 0,2
2011-2014* 21,1 5,0 1,5 0,5 0,9 0,6 0,2 0,2
2015-2018 * 13,3 3,4 1,12 0,43 0,47 0,28 0,12 0,36
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